Abstract
Medullary thyroid cancer (MTC) is considered as a rare thyroid cancer. Surgical approaches such as, total thyroidectomy and bilateral lymph node dissection, represent the first-line treatment. Persistent or increasing serum levels of tumor markers, such as CEA and calcitonin, imply residual or recurrent disease. An early and precise detection of recurrence is very important for guiding appropriate treatment. Recent developments in positron emission tomography (PET) imaging with different radiopharmaceuticals targeting specific hallmark of MTC, such as 18F-DOPA and 18F-FDG, have offered increased sensitivity for identifying recurrences. Moreover, the ability of conventional scintigraphic imaging to guide the surgical approach can be useful for the treatment of MTC recurrent patients. In the present work, we reported two cases of patients with recurrent MTC sending to surgical treatment guided by “nuclear medicine approaches”.
Keywords: 18F-DOPA PET/CT, 18F-FDG PET/CT, 99mTc-sestamibi, medullary thyroid cancer, radio-guided surgery, recurrence.
Current Radiopharmaceuticals
Title:18F-DOPA and 18F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports
Volume: 7 Issue: 2
Author(s): Laura Evangelista, Mohsen Farsad, Andrea Piotto and Maria R. Pelizzo
Affiliation:
Keywords: 18F-DOPA PET/CT, 18F-FDG PET/CT, 99mTc-sestamibi, medullary thyroid cancer, radio-guided surgery, recurrence.
Abstract: Medullary thyroid cancer (MTC) is considered as a rare thyroid cancer. Surgical approaches such as, total thyroidectomy and bilateral lymph node dissection, represent the first-line treatment. Persistent or increasing serum levels of tumor markers, such as CEA and calcitonin, imply residual or recurrent disease. An early and precise detection of recurrence is very important for guiding appropriate treatment. Recent developments in positron emission tomography (PET) imaging with different radiopharmaceuticals targeting specific hallmark of MTC, such as 18F-DOPA and 18F-FDG, have offered increased sensitivity for identifying recurrences. Moreover, the ability of conventional scintigraphic imaging to guide the surgical approach can be useful for the treatment of MTC recurrent patients. In the present work, we reported two cases of patients with recurrent MTC sending to surgical treatment guided by “nuclear medicine approaches”.
Export Options
About this article
Cite this article as:
Evangelista Laura, Farsad Mohsen, Piotto Andrea and Pelizzo R. Maria, 18F-DOPA and 18F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports, Current Radiopharmaceuticals 2014; 7 (2) . https://dx.doi.org/10.2174/1874471007666141027151130
DOI https://dx.doi.org/10.2174/1874471007666141027151130 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multidisciplinary Treatment of Early Stage Endometrial Cancer
Anti-Cancer Agents in Medicinal Chemistry Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease)
Current Radiopharmaceuticals The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry The Correlated Factors of Serum CA19-9 Levels in Diabetic Patients
Current Diabetes Reviews Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications
Current Medicinal Chemistry Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Hepatitis C Treatment in Patients with Drug Addiction: Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects
Current Drug Abuse Reviews MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art
Current Cancer Therapy Reviews Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Probing Protein Binding Sites by Circular Dichroism Spectroscopy
Current Drug Discovery Technologies Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma
Current Genomics Current and Future Development of Estrogen Receptor Ligands: Applications in Estrogen-Related Cancers
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets